Vertex Pharmaceuticals Reports Q2 2026 Financial Results

What Happened
On August 3, 2026, Vertex Pharmaceuticals Incorporated announced and filed a Form 8-K to disclose a press release reporting its consolidated financial results for the three and six months ended June 30, 2026. The press release is attached to the Form 8-K as Exhibit 99.1; the filing also includes an Inline XBRL cover page (Exhibit 104). The company notes the Exhibit 99.1 press release is furnished and not “filed” for purposes of Section 18 of the Exchange Act.

Key Details

• Press release announcing consolidated financial results was issued on August 3, 2026.
• Results cover the three-month and six-month periods ended June 30, 2026 (Q2 2026 and year-to-date).
• Press release is attached as Exhibit 99.1 to the Form 8-K.
• Inline XBRL cover page included as Exhibit 104 for machine-readable financial data; Exhibit 99.1 is furnished, not filed under Section 18.

Why It Matters
This Form 8-K is a routine but material disclosure: the announced quarterly and six-month financial results provide investors with the company’s latest earnings and revenue performance for Q2 2026 and year-to-date figures. The attached press release and XBRL data give investors and analysts the official numbers and machine-readable tags to update models, compare performance, and make investment decisions based on Vertex’s recent operating results.